These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 35429022)

  • 1. Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.
    Hung CH; Yang TY; Wei JC
    Aliment Pharmacol Ther; 2022 May; 55(9):1233-1234. PubMed ID: 35429022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe?
    Levartovsky A; Ben-Horin S
    J Crohns Colitis; 2022 May; 16(4):517-518. PubMed ID: 34626174
    [No Abstract]   [Full Text] [Related]  

  • 3. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.
    Robinson PC; Liew DFL; Liew JW; Monaco C; Richards D; Shivakumar S; Tanner HL; Feldmann M
    Med; 2020 Dec; 1(1):90-102. PubMed ID: 33294881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Kokkotis G; Kitsou K; Bamias G
    Aliment Pharmacol Ther; 2022 May; 55(9):1235-1236. PubMed ID: 35429035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia.
    Jia F; Wang G; Xu J; Long J; Deng F; Jiang W
    Aging (Albany NY); 2021 Nov; 13(21):23895-23912. PubMed ID: 34725309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.
    Velloso LA
    JAMA Netw Open; 2021 Oct; 4(10):e2129707. PubMed ID: 34661668
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.
    Kokkotis G; Kitsou K; Xynogalas I; Spoulou V; Magiorkinis G; Trontzas I; Trontzas P; Poulakou G; Syrigos K; Bamias G
    Aliment Pharmacol Ther; 2022 Jan; 55(2):154-167. PubMed ID: 34881430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
    Chen XY; Yan BX; Man XY
    Ther Adv Respir Dis; 2020; 14():1753466620926800. PubMed ID: 32436460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.
    Messina F; Pampaloni F; Piaserico S
    Ann Rheum Dis; 2021 May; 80(5):e79. PubMed ID: 32816688
    [No Abstract]   [Full Text] [Related]  

  • 10. [Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].
    Steinchen N; Müller-Ladner U; Lange U
    Z Rheumatol; 2020 Aug; 79(6):574-577. PubMed ID: 32514854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    Chanchlani N; Lin S; Chee D; Hamilton B; Nice R; Arkir Z; Bewshea C; Cipriano B; Derikx LAAP; Dunlop A; Greathead L; Griffiths RL; Ibraheim H; Kelleher P; Kok KB; Lees CW; MacDonald J; Sebastian S; Smith PJ; McDonald TJ; Irving PM; Powell N; Kennedy NA; Goodhand JR; Ahmad T
    J Crohns Colitis; 2022 Mar; 16(3):389-397. PubMed ID: 34473254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina
    Duret PM; Spielmann L; Messer L
    Ann Rheum Dis; 2021 May; 80(5):e80. PubMed ID: 32816687
    [No Abstract]   [Full Text] [Related]  

  • 13. Should patients stop their biologic treatment during the COVID-19 pandemic.
    Bashyam AM; Feldman SR
    J Dermatolog Treat; 2020 Jun; 31(4):317-318. PubMed ID: 32191143
    [No Abstract]   [Full Text] [Related]  

  • 14. Biologics, spondylitis and COVID-19.
    Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
    Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 in patients with rheumatological diseases treated with anti-TNF.
    Brito CA; Paiva JG; Pimentel FN; Guimarães RS; Moreira MR
    Ann Rheum Dis; 2021 May; 80(5):e62. PubMed ID: 32546603
    [No Abstract]   [Full Text] [Related]  

  • 16. Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.
    Marino A; Romano M; Gattinara M; Cimaz R
    Semin Arthritis Rheum; 2020 Dec; 50(6):1214-1215. PubMed ID: 33059294
    [No Abstract]   [Full Text] [Related]  

  • 17. The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists.
    Cappello M; Busacca A; Guida L
    Gastroenterology; 2021 Apr; 160(5):1885-1886. PubMed ID: 32645320
    [No Abstract]   [Full Text] [Related]  

  • 18. Ambulatory management of perianal Crohn's disease during the COVID-19 pandemic.
    Divizia A; Sensi B; Sica GS
    Colorectal Dis; 2020 Jun; 22(6):645-646. PubMed ID: 32348620
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito
    D'Silva KM; Serling-Boyd N; Wallwork R; Hsu T; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2021 May; 80(5):e64. PubMed ID: 32546600
    [No Abstract]   [Full Text] [Related]  

  • 20. Favorable outcome of COVID-19 in a young woman with severe Crohn's disease on regular use of adalimumab and prednisone: a case report.
    Vechi HT; Maia LR; Alves MDM; Rodrigues-Neto JF
    Rev Inst Med Trop Sao Paulo; 2020; 62():e102. PubMed ID: 33331521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.